Cdc25a - cell division cycle 25A Gene

Also Known as D9Ertd393e

Species: Mus musculus

Gene Type: protein coding
Gene ID: 12530

Summary

Predicted to enable chaperone binding activity; protein kinase binding activity; and protein tyrosine Phosphatase activity. Predicted to be involved in several processes, including mitotic cell cycle phase transition; positive regulation of cell cycle G2/M phase transition; and positive regulation of cholangiocyte proliferation. Predicted to act upstream of or within cell division. Located in cytoplasm and nucleus. Is expressed in several structures, including adrenal gland; central nervous system; gonad; gut; and thymus. Human ortholog(s) of this gene implicated in autosomal recessive polycystic kidney disease; cervical cancer; prostate cancer; and urinary bladder Cancer. Orthologous to human CDC25A (cell division cycle 25A). [provided by Alliance of Genome Resources, Apr 2022]

Cdc25a Products (6)

mRNA Protein Name
NM_001410385.1 NP_001397314.1 M-phase inducer phosphatase 1 isoform 2
NM_001410386.1 NP_001397315.1 M-phase inducer phosphatase 1 isoform 3
NM_001410387.1 NP_001397316.1 M-phase inducer phosphatase 1 isoform 4
NM_001410388.1 NP_001397317.1 M-phase inducer phosphatase 1 isoform 5
NM_001410389.1 NP_001397318.1 M-phase inducer phosphatase 1 isoform 5
NM_007658.4 NP_031684.3 M-phase inducer phosphatase 1 isoform 1

Gene Ontology

  • Cellular Component
Cellular Component GO Annotation Evidence Références Source
located in cytoplasm IDA
IDA: Inferred from direct assay
11981756 MGI
located in nucleus IDA
IDA: Inferred from direct assay
11981756 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

M-phase inducer phosphatase 1

  • dual specificity phosphatase Cdc25A

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (1)
Cat. No. Nom du produit Effect
Pureté Phase
HY-18174H Prexasertib lactate / Phase 2

Pre-clinical Phase

Bioactive Molecules (27)
Cat. No. Nom du produit
Effect
Pureté
Rare Diseases
HY-18174 Prexasertib 99.64% Unkown
HY-108543 NSC 95397 99.0% Unkown
HY-100034 NSC 663284 Inhibitor 99.29% Unkown
HY-18174A Prexasertib dihydrochloride 99.73% Unkown
HY-18174E Prexasertib dimesylate 98.90% Unkown
HY-132578 M5N36 Inhibitor 98.00% Unkown
HY-112776A BN82002 hydrochloride Inhibitor 99.36% Unkown
HY-121065 BN-82685 Inhibitor 99.05% Unkown
HY-128769 M2N12 Inhibitor 98.19% Unkown
HY-N7045 Isosilybin B 99.32% Unkown
HY-155816 PROTAC NSD3 degrader-1 99.40% Unkown
HY-W024644 Hydroxyethylthio Vitamine K3 ≥97.0% Unkown
HY-18174B Prexasertib Mesylate Hydrate / Unkown
HY-112776 BN82002 Inhibitor / Unkown
HY-118529 JUN-1111 Inhibitor 98.57% Unkown
HY-RS02291 CDC25A Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-18174C Prexasertib mesylate / Unkown
HY-178295 VHR-IN-5 Inhibitor / Unkown
HY-178296 VHR-IN-6 Inhibitor / Unkown
HY-178297 VHR-IN-7 Inhibitor / Unkown
HY-178301 VHR-IN-9 Inhibitor / Unkown
HY-181011 PROTAC Cdc25 degrader-1 / Unkown
HY-184446 CDC25A/NF-κB-IN-1 / Unkown
HY-28086 CDC25-IN-2 Inhibitor / Unkown
HY-P4979 Cdc25A (80-93) (human) / Unkown
HY-RS17278 Cdc25a Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23732 Cdc25a Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cdc25a NCBI NCBI:993